Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14

[1]  M. M. Rahman,et al.  Worldwide trends in diabetes since 1980 : pooled analysis of 751 population-based measurement studies with over 4 . 4 million participants , 2016 .

[2]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[3]  Carol Coupland,et al.  Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care , 2016, British Medical Journal.

[4]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[5]  A. Tenenbaum,et al.  Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure , 2017, Cardiovascular Diabetology.

[6]  Michael E. Miller,et al.  The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study , 2010, BMJ : British Medical Journal.

[7]  A. Sharrett,et al.  The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes , 2017, Diabetes Care.

[8]  S. Heller,et al.  Insulin Degludec Has Lower Hypoglycemia Risk than Insulin Glargine U100 in Older People with Type 2 Diabetes (T2D) , 2018, Diabetes.

[9]  Adrian F. Hernandez,et al.  The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes , 2018, Clinical cardiology.

[10]  W. Hundley,et al.  Heart failure prevalence, incidence, and mortality in the elderly with diabetes. , 2004, Diabetes care.

[11]  G. Filippatos,et al.  Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.

[12]  M. Pfeffer,et al.  Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction , 2018, European heart journal. Acute cardiovascular care.

[13]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[14]  M. Pfeffer,et al.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.

[15]  Bereket T. Tesfaldet,et al.  Endpoints in diabetes cardiovascular outcome trials , 2018, The Lancet.

[16]  Sumit R. Majumdar,et al.  Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database , 2010, Diabetes Care.

[17]  R. Holman,et al.  Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype , 2018, Diabetes Care.

[18]  N. Rege,et al.  ICH Harmonised Tripartite Guideline: guideline for good clinical practice. , 2001, Journal of postgraduate medicine.

[19]  M. Hanefeld,et al.  Is Hyperglycemia a Cardiovascular Risk Factor? , 2011, Diabetes Care.

[20]  T. Heise,et al.  A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance , 2014, Clinical Pharmacokinetics.

[21]  B. Zinman,et al.  Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes , 2017, The New England journal of medicine.

[22]  P. Valensi,et al.  Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group , 2016, Cardiovascular Diabetology.

[23]  N. Tentolouris,et al.  Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes. , 2018, Annals of translational medicine.

[24]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[25]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[26]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[27]  S. Preston,et al.  Deaths Attributable to Diabetes in the United States: Comparison of Data Sources and Estimation Approaches , 2017, PloS one.

[28]  B. Frier.  How hypoglycaemia can affect the life of a person with diabetes , 2008, Diabetes/metabolism research and reviews.

[29]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[30]  M. Davies,et al.  Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). , 2007, European heart journal.

[31]  S. Yusuf,et al.  Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. , 2013, European heart journal.

[32]  B. Zinman,et al.  DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality , 2017, Diabetologia.

[33]  P. Hsu,et al.  Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes , 2013, Diabetes Care.

[34]  K. Dickstein,et al.  Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes , 2017, European journal of heart failure.

[35]  B. Zinman,et al.  Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial , 2019, European heart journal.

[36]  G. Dailey.  Overall mortality in diabetes mellitus: where do we stand today? , 2011, Diabetes technology & therapeutics.

[37]  M. Pfeffer,et al.  Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction , 2018 .

[38]  E. Abel,et al.  Insulin Signaling and Heart Failure. , 2016, Circulation research.

[39]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[40]  Spiros Denaxas,et al.  Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.

[41]  Yu-qi Fan,et al.  Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus , 2018, Cardiovascular Diabetology.

[42]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[43]  A. Bhargava,et al.  Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial , 2017, JAMA.

[44]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[45]  S. Gough,et al.  Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials , 2012, Diabetes, obesity & metabolism.

[46]  B. Zinman,et al.  Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience , 2018, Diabetes Care.

[47]  P. Bundhun,et al.  Comparing the Clinical Outcomes Between Insulin-treated and Non-insulin-treated Patients With Type 2 Diabetes Mellitus After Coronary Artery Bypass Surgery , 2016, Medicine.

[48]  G. Nichols,et al.  Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. , 2001, Diabetes care.

[49]  B. Zinman,et al.  Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. , 2016, American heart journal.

[50]  P. Valensi,et al.  Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group , 2018, Cardiovascular Diabetology.

[51]  W. Cushman,et al.  Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial , 2017, Diabetes, obesity & metabolism.